STOCK TITAN

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Acutus Medical has granted 54,700 restricted stock units (RSUs) to seven newly hired employees as part of its 2022 Inducement Equity Incentive Plan. Approved by the Compensation Committee on April 1, 2023, these RSUs will vest over four years, subject to continued employment. This initiative aligns with Acutus' goal to enhance its workforce as it seeks to improve diagnostics and treatments for cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, Acutus aims to advance electrophysiology through innovative products and strategic partnerships while closely managing its expenses and cash burn.

Positive
  • Granting of 54,700 RSUs may attract and retain talent, enhancing company capabilities.
  • The initiative demonstrates proactive workforce expansion amid ongoing product development efforts.
Negative
  • None.

CARLSBAD, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on April 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 7 individuals hired by Acutus in March 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received, in the aggregate, 54,700 restricted stock units (“RSUs”). One-fourth of the RSUs granted to each employee will vest yearly on each anniversary of the grant date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the grant date, in each case, subject to each such employee’s continued employment with Acutus on such vesting date.

About Acutus Medical, Inc.
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “will,” “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of its products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase the Company’s systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally, including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the coronavirus (COVID-19) pandemic and Acutus’ response to it, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Caroline Corner
Westwicke ICR
D: 415-202-5678
caroline.corner@westwicke.com


FAQ

What is the significance of the RSUs granted by Acutus Medical on April 1, 2023?

The RSUs are part of their employment inducement strategy to attract talent.

How many employees received RSUs from Acutus Medical?

Seven employees received a total of 54,700 RSUs.

When will the RSUs granted by Acutus Medical fully vest?

The RSUs will vest fully on the fourth anniversary of the grant date, April 1, 2027.

What is Acutus Medical focused on?

Acutus Medical focuses on improving the diagnosis and treatment of cardiac arrhythmias.

ACUTUS MEDICAL INC

OTC:AFIB

AFIB Rankings

AFIB Latest News

AFIB Stock Data

1.77M
27.23M
8.98%
0.01%
1.86%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
CARLSBAD